{
    "clinical_study": {
        "@rank": "130970", 
        "arm_group": [
            {
                "arm_group_label": "Normal control", 
                "arm_group_type": "Sham Comparator", 
                "description": "Normal patient placebo"
            }, 
            {
                "arm_group_label": "Glaucoma suspect", 
                "arm_group_type": "Sham Comparator", 
                "description": "Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)"
            }, 
            {
                "arm_group_label": "Newly diagnosed glaucoma", 
                "arm_group_type": "Experimental", 
                "description": "Treated with Travoprost (0.04%)"
            }
        ], 
        "brief_summary": {
            "textblock": "Glaucoma is the second leading cause of blindness among seniors in Canada. It is often\n      associated with an elevated intraocular pressure (IOP), but its exact mechanism is still\n      largely unknown. Some studies have shown a link between glaucoma and changes in the amount\n      of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular\n      veins among three different groups using a spectrophotometer. This instrument is linked to a\n      camera and can measure the quantity of oxygen in the veins using different characteristics\n      of the blood inside.\n\n      The groups of the study are: patients without glaucoma, patients suspected of glaucoma and\n      patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost\n      0.004%, will only be administered to the groups suspected or diagnosed with glaucoma.\n      Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten\n      patients will be recruited into each group for a total of 30 patients in this study. All\n      patients for the suspected or diagnosed groups will be recruited from the Jewish General\n      Hospital. Subsequently all testing will be done at the \u00c9cole d'optom\u00e9trie, Universit\u00e9 de\n      Montr\u00e9al"
        }, 
        "brief_title": "Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Open Angle Glaucoma", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  good systemic health\n\n          -  irido-corneal angle open\n\n          -  intraocular pressure more than 18 mmHg\n\n        Exclusion Criteria:\n\n          -  having cardiovascular problem\n\n          -  Hypertension or diabetes\n\n          -  under systemic medication for high blood pressure\n\n          -  had an ocular surgery in the past"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711177", 
            "org_study_id": "OPM3117-Dubois/Pham"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Normal control", 
                    "Glaucoma suspect"
                ], 
                "description": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }, 
            {
                "arm_group_label": "Newly diagnosed glaucoma", 
                "description": "Travatan Z is administered to newly diagnosed glaucoma patient", 
                "intervention_name": "travoprost", 
                "intervention_type": "Drug", 
                "other_name": "travatan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Travoprost"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "primary open angle glaucoma", 
            "retinal oximetry"
        ], 
        "lastchanged_date": "October 19, 2012", 
        "location": {
            "contact": {
                "email": "pierre.forcier@umontreal.ca", 
                "last_name": "Pierre Forcier, MSc", 
                "phone": "514-343-7468"
            }, 
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H3t1P1"
                }, 
                "name": "University of Montreal"
            }, 
            "investigator": [
                {
                    "last_name": "Pierre Forcier, MSc", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Vasile Diaconu, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Oskar Kasner, md FRCSC", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For each subject, all the measurements will be done during an 1 hour appointment.", 
            "measure": "Blood oxygenation", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711177"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e9 de Montr\u00e9al", 
            "investigator_full_name": "Pierre Forcier", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Universit\u00e9 de Montr\u00e9al", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universit\u00e9 de Montr\u00e9al", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}